Evaluating complicated pneumonia in children in South-East Europe
Increasing Incidence of Complicated Pneumonia in Children in South-East Europe: a Retrospective Multi-center Analysis of Incidence, Characteristics and Outcomes
This study looks at how complicated pneumonia affects children in South-East Europe to see what causes it, how serious it can be, and what treatments work best.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 1 Month to 18 Years |
| Sex | All |
| Sponsor | Mother and Child Health Institute of Serbia Dr Vukan Cupic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Belgrade) |
| Trial ID | NCT06657898 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical course of complicated community-acquired pneumonia in children, focusing on cases of necrotizing pneumonia. It will analyze the etiological agents involved, their association with disease severity and outcomes, and evaluate therapeutic approaches, complications, and both short-term and long-term outcomes. The study will collect data from pediatric centers across South-East Europe over a ten-year period, reviewing medical charts to gather standardized information on various clinical parameters.
Who should consider this trial
Good fit: Ideal candidates are children aged 1 month to 18 years diagnosed with complicated community-acquired pneumonia who were hospitalized during the study period.
Not a fit: Patients with increased risk for severe lung infections or those with hospital-acquired pneumonia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding and management of complicated pneumonia in children, leading to better treatment outcomes.
How similar studies have performed: Other studies have shown success in evaluating pneumonia in children, but this specific focus on complicated cases in South-East Europe is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Children aged 1 month to 18 years of age * Children diagnosed with complicated community acquired pneumonia (pneumonia with parapneumonic effusion, necrotizing pneumonia and lung abscess) * Children who were hospitalized from January 1st 2014 to April 30th 2024 and required at least 24 hours of hospital stay Exclusion Criteria * Children with increased risk for severe lung infections (cystic fibrosis, primary ciliary dyskinesia, immunodeficiencies, congenital lung abnormalities, neurological conditions, chemotherapy) * Children with hospital-acquired pneumonia
Where this trial is running
Belgrade
- IMotherChildHealth — Belgrade, Serbia (Recruiting)
Study contacts
- Study coordinator: Aleksandar Sovtic, M.D. Ph.D
- Email: aleksandar.sovtic@imd.org.rs
- Phone: +381113108158
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.